Literature DB >> 29888210

Hepatic Arterial Infusion Chemotherapy: A Potential Therapeutic Option for Hepatocellular Carcinoma with Portal Vein Tumor Thrombus.

Michihisa Moriguchi1, Takeshi Aramaki2, Toshihiro Tanaka3, Yoshito Itoh1.   

Abstract

Entities:  

Year:  2018        PMID： 29888210      PMCID： PMC5985412          DOI： 10.1159/000488156

Source DB:  PubMed          Journal:  Liver Cancer        ISSN： 1664-5553            Impact factor:   11.740


× No keyword cloud information.
  6 in total

Review 1.  Current Status of Hepatic Arterial Infusion Chemotherapy.

Authors:  Shuntaro Obi; Shinpei Sato; Toshihiro Kawai
Journal:  Liver Cancer       Date:  2015-08-12       Impact factor: 11.740

2.  Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma: a randomised phase 3 non-inferiority trial.

Authors:  Masatoshi Kudo; Richard S Finn; Shukui Qin; Kwang-Hyub Han; Kenji Ikeda; Fabio Piscaglia; Ari Baron; Joong-Won Park; Guohong Han; Jacek Jassem; Jean Frederic Blanc; Arndt Vogel; Dmitry Komov; T R Jeffry Evans; Carlos Lopez; Corina Dutcus; Matthew Guo; Kenichi Saito; Silvija Kraljevic; Toshiyuki Tamai; Min Ren; Ann-Lii Cheng
Journal:  Lancet       Date:  2018-03-24       Impact factor: 79.321

3.  Phase I/II study of radiologic hepatic arterial infusion of fluorouracil plus systemic irinotecan for unresectable hepatic metastases from colorectal cancer: Japan Clinical Oncology Group Trial 0208-DI.

Authors:  Yasuaki Arai; Atsushi Ohtsu; Yozo Sato; Takeshi Aramaki; Ken Kato; Madoka Hamada; Kei Muro; Yasuhide Yamada; Yoshitaka Inaba; Yasuhiro Shimada; Narikazu Boku; Yoshito Takeuchi; Sojiro Morita; Mitsuo Satake
Journal:  J Vasc Interv Radiol       Date:  2012-08-24       Impact factor: 3.464

4.  Sorafenib plus low-dose cisplatin and fluorouracil hepatic arterial infusion chemotherapy versus sorafenib alone in patients with advanced hepatocellular carcinoma (SILIUS): a randomised, open label, phase 3 trial.

Authors:  Masatoshi Kudo; Kazuomi Ueshima; Osamu Yokosuka; Sadahisa Ogasawara; Shuntaro Obi; Namiki Izumi; Hiroshi Aikata; Hiroaki Nagano; Etsuro Hatano; Yutaka Sasaki; Keisuke Hino; Takashi Kumada; Kazuhide Yamamoto; Yasuharu Imai; Shouta Iwadou; Chikara Ogawa; Takuji Okusaka; Fumihiko Kanai; Kohei Akazawa; Ken-Ichi Yoshimura; Philip Johnson; Yasuaki Arai
Journal:  Lancet Gastroenterol Hepatol       Date:  2018-04-07

5.  Sorafenib versus Hepatic Arterial Infusion Chemotherapy as Initial Treatment for Hepatocellular Carcinoma with Advanced Portal Vein Tumor Thrombosis.

Authors:  Michihisa Moriguchi; Takeshi Aramaki; Hideyuki Nishiofuku; Rui Sato; Koiku Asakura; Kanji Yamaguchi; Toshihiro Tanaka; Masahiro Endo; Yoshito Itoh
Journal:  Liver Cancer       Date:  2017-08-29       Impact factor: 11.740

6.  Response to chemotherapy improves hepatic reserve for patients with hepatocellular carcinoma and Child-Pugh B cirrhosis.

Authors:  Takeshi Terashima; Tatsuya Yamashita; Kuniaki Arai; Kazunori Kawaguchi; Kazuya Kitamura; Taro Yamashita; Yoshio Sakai; Eishiro Mizukoshi; Masao Honda; Shuichi Kaneko
Journal:  Cancer Sci       Date:  2016-09-01       Impact factor: 6.716
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.